-
Recent IPO Optinose Reeks Of Opportunity, Jefferies Names It A Buy
Tuesday, November 7, 2017 - 4:07pm | 354Read More...OptiNose Inc (NASDAQ: OPTN) hit the market recently. It's a specialty pharma company developing innovative products for treating diseases related to ear, nose and throat and for allergy. With the quiet period following the IPO expiring, Jefferies initiated coverage of the company. The Analyst...
-
Mylan's Generic Copaxone Arrives, Teva Sales To Take A Hit
Wednesday, October 4, 2017 - 11:40am | 350Read More...The FDA dealt yet another blow to struggling Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) investors by approving rival Mylan N.V. (NASDAQ: MYL)’s generic version of Teva’s Copaxone multiple sclerosis drug. Analysts say generic competition was not factored into Teva’s...
-
Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision
Wednesday, November 16, 2016 - 2:38pm | 698Read More...Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) hit a new 52-week low of $37.25 on Tuesday after the company reported its third-quarter results and provided a concerning outlook for the full year given some concerns over its specialty drugs. The stock rebounded slightly on Wednesday...
-
Jefferies Warns Of 'Too Many Headwinds' For Teva
Wednesday, November 16, 2016 - 10:42am | 256Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) reduced its Q4 and FY 2016 outlook. This could be an indication of greater weakness in generics in 2017 and an increased chance of the 40mg Copaxone generic being launched, Jefferies’ David Steinberg said in a report. Steinberg downgraded...
-
Valeant Has 'Strong' Presence At AAD Meeting, Analyst Says
Wednesday, March 9, 2016 - 11:31am | 309Read More...Jefferies’ David Steinberg maintained a Buy rating for Valeant Pharmaceuticals Intl Inc (NYSE: VRX), with a price target of $106, after attending the AAD conference. “Valeant once again maintained a very strong presence at the AAD this year, securing one of the 4 largest booths in...
-
Long-Time Valeant Bull Jefferies Cuts Price Target 40%
Tuesday, March 1, 2016 - 10:27am | 278Read More...Jefferies' David Steinberg maintained a Buy rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), while lowering the price target from $172 to $106. Steinberg mentioned that CEO Mike Pearson had returned to his position following a severe bout of pneumonia. At the same time, the company withdrew...
-
This Development Will Hurt Valeant Investor Sentiment Even More
Monday, February 29, 2016 - 1:20pm | 426Read More...The news of generic challenger for Xifaxan 550mg is brought down the shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX). Though Valeant has adequate patent protection for the drug, the recent news added fuel to the negative investor sentiment on the stock, which has dropped 63 percent in the...
-
Jefferies Cuts Valeant Target, But Still Sees $172 Upside
Monday, November 2, 2015 - 10:48am | 295Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares have plummeted 63 percent in the last three months, and are trading significantly below their 52-week high of $263.81. Jefferies’ David Steinberg maintained a Buy rating on the company, while reducing the price target from $224 to $...
-
Who's The Next Big Pharma Acquisition?
Friday, May 29, 2015 - 11:20am | 629Read More...In a new report, Jefferies analyst David Steinberg looked at the frenzy of M&A activity that has been happening in the specialty pharmaceuticals space in recent years. According to the report, 2014 was a blockbuster year for buyouts, and 2015 is on pace to be a record year. Perfect M&A...
-
Jefferies Downgrades Salix Pharmaceuticals As Raised Bid By Valeant Appears Final
Wednesday, March 18, 2015 - 10:03am | 132Read More...In a report published Wednesday, Jefferies analyst David Steinberg downgraded the rating on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) from Buy to Hold, but raised the price target from $149.00 to $173.00. In the report, Jefferies noted, "After a litany of suitors cast their bids, SLXP has agreed...
-
Barclays Raises Valeant Pharmaceuticals' Price Target
Friday, January 9, 2015 - 5:35pm | 252Read More...Barclays raised its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from $149 to $179 Friday and maintained a Buy rating. Analyst David Steinberg noted that the “surprisingly strong rev guidance (implied 14-15 percent Y/Y growth) is ~$150M ahead of the co’s prior 3Q14...
-
Jefferies Sees Acquisition Of Salix Pharmaceuticals As Being Even More Likely Now
Friday, November 7, 2014 - 11:39am | 177Read More...In a note published Friday, Jefferies analyst David Steinberg published a note on Salix Pharmaceuticals (NASDAQ: SLXP) that commented on the likelihood of Allergan's (NYSE: AGN) acquisition of the company. In the report, Jefferies noted, "In hindsight, it makes perfect sense. The “overstuffed”...
-
UPDATE: Jefferies Initiates Coverage On Amphastar Pharmaceuticals
Monday, July 21, 2014 - 11:38am | 139Read More...In a note released Monday morning Jefferies analyst David Steinberg initiated coverage on Amphastar Pharmaceuticals (NASDAQ: AMPH) with a Buy rating and a $14 price target. Steinberg wrote, "Unlike most of its competitors, Amphastar has the skills and technology to successfully tackle some...
-
Getting The U.S. Economy In Order with David Steinberg and Robert Kaplan
Monday, April 29, 2013 - 10:22am | 595Read More...The United States is facing challenges with growth and tightening austerity measures can strike uncertainty into the hearts of many. The country is changing how it handles its money, and sequestration was only the beginning. David Steinberg, founder of DLS Capital Management, and Robert Kaplan,...
-
Auxilium's Xiaflex Launch Slow, But Significant Opportunity Remains (AUXL)
Tuesday, July 13, 2010 - 10:58am | 199Read More...Deutsche Bank analysts David Steinberg, Edward Chung, and Rosemary Wang maintained a Buy rating for Auxilium Pharmaceuticals (NASDAQ: AUXL), but dropped their price target $10. Auxilium's new drug Xiaflex had a slow launch, falling $2 million short of consensus Q2 estimate of $4 million for Xiaflex...
